Potential prolongation of PFS in mantle cell lymphoma after R-HyperCVAD: auto-SCT consolidation or rituximab maintenance.

Ahmadi, T; McQuade, J; Porter, D; Frey, N; Loren, A W; Goldstein, S C; Svoboda, J; Stadtmauer, E; Schuster, S J; Nasta, S D

Ahmadi, T; McQuade, J; Porter, D; Frey, N; Loren, A W; Goldstein, S C; Svoboda, J; Stadtmauer, E; Schuster, S J; Nasta, S D.

Affiliation

Ahmadi T; Division of Hematology/Oncology, Abramson Cancer Center, University of Pennsylvania, 34th and Spruce Street, Philadelphia, PA 19104, USA. Tahamtan.ahmadi@uphs.upenn.edu

Bone Marrow Transplant ; 47(8): 1082-6, 2012 Aug.

Article in En | MEDLINE | ID: mdl-22080969

Subject(s)

Antibodies, Monoclonal, Murine-Derived/administration & dosage; Antineoplastic Combined Chemotherapy Protocols/administration & dosage; Lymphoma, Mantle-Cell/mortality; Lymphoma, Mantle-Cell/therapy; Stem Cell Transplantation; Disease-Free Survival; Female; Follow-Up Studies; Humans; Lymphoma, Mantle-Cell/pathology; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Rituximab; Survival Rate; Time Factors; Transplantation, Autologous

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Health context: 6_ODS3_enfermedades_notrasmisibles Database: MEDLINE Main subject: Antineoplastic Combined Chemotherapy Protocols / Lymphoma, Mantle-Cell / Stem Cell Transplantation / Antibodies, Monoclonal, Murine-Derived Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Female / Humans / Male / Middle aged Language: En Journal: Bone Marrow Transplant Year: 2012 Document type: Article

Fulltext

XML

PubMed Links

Search on Google